Moderna's mRNA Flu Vaccine, mFLUSIVA, Receives FDA Approval for Adults 50 and Older
Moderna has announced the approval of a new seasonal flu vaccine by the U.S. Food and Drug Administration that utilizes mRNA technology. The vaccine, named mFLUSIVA, is specifically approved for adults aged 50 and older. This marks a significant milestone as it is the first influenza vaccine using mRNA technology to receive FDA approval. Moderna expressed gratitude to all involved in the clinical trials, regulatory process, and their own teams for making this achievement possible.
Earlier this year, the FDA initially declined to consider Moderna's application for the flu vaccine. However, they later reversed their decision and allowed the vaccine to proceed to review. The approval was based on the results of a 40,000-person clinical trial that demonstrated the new vaccine's superior effectiveness in adults aged 50 and older compared to traditional flu shots currently in use.
As this is a developing story, further updates may follow regarding the new flu vaccine from Moderna. The approval of mFLUSIVA represents a significant advancement in utilizing mRNA technology to address public health challenges. Moderna's commitment to scientific innovation and collaboration has led to this important milestone in flu vaccine development.